Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2025-09-04 Transaction in Own Shar…
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1
Transaction in Own Shares Classification · 95% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1' and is filed with the U.S. Securities and Exchange Commission. It is a post-effective amendment to a Form F-1 registration statement under the Securities Act of 1933. The text includes detailed information about the registration statement, the selling shareholder, the securities involved (American Depositary Shares), and the terms of the offering. It is a regulatory filing related to securities registration and offering, specifically a post-effective amendment to a registration statement, which is a type of capital markets filing. This type of document is best classified under 'Transaction in Own Shares' (POS) because it relates to the registration and resale of shares by a selling shareholder under a standby equity purchase agreement, which involves transactions in the company's own shares. The document is lengthy (15,000 characters) and contains substantive information about the offering, not merely an announcement or certification, so it is not an RPA or RNS. Therefore, the most appropriate classification is POS with high confidence.
2025-09-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Scinai Immunotherapeutics Ltd. It includes a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects for the first half of 2025. The presence of condensed interim unaudited financial statements and an operating and financial review indicates this is a comprehensive interim report for a period shorter than a full fiscal year. The document length is 2803 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-09-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an explanatory note about a press release issued on June 12, 2025, regarding new funding and CDMO growth. The document is short (1983 characters) and primarily serves to furnish a press release rather than containing detailed financial statements or comprehensive report content. It does not contain actual financial data or detailed analysis but rather references an external press release. According to the rules, such documents that announce or furnish reports or press releases without substantive financial data should be classified as Regulatory Filings (RNS).
2025-06-12 English
PROSPECTUS SUPPLEMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Scinai Immunotherapeutics Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release announcing the receipt of Italian government clearance for a potential acquisition of Pincell S.r.l. The document is not a full financial report but rather a regulatory announcement about a corporate event (government clearance for acquisition). It does not contain financial statements or detailed financial analysis. The document also references the prospectus supplement and other filings but is itself a standalone regulatory update. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories such as M&A filings or capital updates. The document is about a regulatory approval related to an acquisition but is not the merger filing itself (which would be MA or TAR). Hence, the classification is RNS with high confidence.
2025-06-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to provide current information. It includes an explanatory note about a press release regarding government clearance for a potential acquisition. The document is short (2011 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no detailed financial statements or substantive financial data presented. The document is essentially an announcement of a report (press release) rather than the report itself. According to the rules, such documents are classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full reports or filings like 10-K or M&A filings. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2025-06-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release announcing the publishing of Q1 2025 financial results and includes the press release as an exhibit. The document itself is short (1968 characters) and primarily serves to furnish the press release rather than containing detailed financial statements or analysis. According to the rules, such a document is a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial report or detailed financial data itself. It is not an Earnings Release (ER) because it does not contain the financial highlights directly, only references the press release. It is not an Interim Report (IR) because it lacks substantive financial data or analysis. Therefore, the correct classification is Regulatory Filings (RNS).
2025-06-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.